Wiskott-Aldrich Syndrome Clinical Trial
Official title:
Haploidentical Hematopoietic Stem Cell Transplantation for Pediatric Patients With Wiskott-Aldrich Syndrome: A Pilot Study
Verified date | February 2009 |
Source | St. Jude Children's Research Hospital |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Wiskott - Aldrich syndrome (WAS) is a rare disorder curable only through allogeneic
hematopoietic stem cell transplantation. A mismatched family member is an option when no
human leukocyte antigen (HLA-immune system type) matched related or matched unrelated donor
is available.
This study will evaluate a novel therapeutic strategy for patients with WAS who undergo
haploidentical transplantation using a parental donor. To reduce the risk of
transplant-related toxicities, participants will receive a reduced intensity chemotherapy
and antibody regimen (conditioning treatment). Participants will then receive an infusion of
donor stem cells depleted of certain white blood cells called T- and B-lymphocytes. The stem
cell depletion processing will be done through the use of the investigational CliniMACS
device. A certain number of T-lymphocytes will be added back to the processed stem cell
graft prior to infusion into the recipient.
The primary objective of this study is to determine the safety of haploidentical
transplantation in WAS patients using this specified conditioning regimen and engineered
graft. Safety will be defined in terms of engraftment (meaning how well the graft grows and
functions after infusion) and regimen-related toxicity within the first 100 days after
transplant.
Status | Completed |
Enrollment | 4 |
Est. completion date | February 2009 |
Est. primary completion date | July 2008 |
Accepts healthy volunteers | No |
Gender | Male |
Age group | N/A to 18 Years |
Eligibility |
Inclusion Criteria: - Genotypical diagnosis of Wiskott-Aldrich Syndrome. - Less than 18 years of age at time of transplant. Must meet two of the eight following clinical criteria: - Eczema that is refractory to standard therapy. - Thrombocytopenia as defined by a platelet count < 50,000/mm3. - Significant risk for or presence of opportunistic infection. - Autoimmune disease. - Malignancy or pre-malignant condition. - Family history as defined as a family member with WAS who died before 10 years of age. - Does not have a suitable, available 6/6 HLA-matched sibling donor available for donation. - Does not have a suitable, available 10/10 HLA-allele matched unrelated donor identified through the National Marrow Donor Program (NMDP). Exclusion Criteria: If any of the following clinical indicators are met within 45 days prior to transplant, the research participant will not be eligible for the study: - Symptomatic cardiac disease or evidence of significant cardiac dysfunction by echocardiogram (shortening fraction < 30%). - Creatinine clearance or Tc 99 less than or equal 40ml/min/1.73 m2. - SGPT greater than or equal 500 U/L. - Karnofsky or Lansky Performance Score of < 50. - Pulmonary function tests: FVC < 50% of predicted value if age appropriate to perform the testing adequately or an O2 saturation less than or equal to 92% on room air at rest. |
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | To determine safety in regards to engraftment and toxicity within 100 days post-haploidentical T- and B-cell depleted hematopoietic stem cell transplantation for patients with Wiskott-Aldrich syndrome who received a reduced intensity conditioning | March 2010 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT01652092 -
Allogeneic Hematopoietic Stem Cell Transplant for Patients With Primary Immune Deficiencies
|
N/A | |
Completed |
NCT01953016 -
Participation in a Research Registry for Immune Disorders
|
||
Active, not recruiting |
NCT02333760 -
Long Term Safety Follow up of Haematopoietic Stem Cell Gene Therapy for the Wiskott Aldrich Syndrome
|
Phase 1/Phase 2 | |
Terminated |
NCT01319851 -
Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation
|
N/A | |
Recruiting |
NCT05687474 -
Baby Detect : Genomic Newborn Screening
|
||
Recruiting |
NCT04371939 -
Efficacy and Safety of Romiplostim Versus Eltrombopag in the Treatment of Thrombocytopenia in Patients With Wiskott-Aldrich Syndrome
|
Phase 2 | |
Completed |
NCT01347346 -
Gene Therapy for WAS
|
Phase 1/Phase 2 | |
Recruiting |
NCT01821781 -
Immune Disorder HSCT Protocol
|
Phase 2 | |
Completed |
NCT01289847 -
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
|
Phase 4 | |
Completed |
NCT01347242 -
Gene Therapy for Wiskott-Aldrich Syndrome (WAS)
|
Phase 1/Phase 2 | |
Terminated |
NCT00006054 -
Allogeneic Bone Marrow Transplantation in Patients With Primary Immunodeficiencies
|
N/A | |
Enrolling by invitation |
NCT03198195 -
Post-transplant Cyclophosphamide in Wiskott-Aldrich Syndrome
|
N/A | |
Recruiting |
NCT03019809 -
A Trial of Plerixafor/G-CSF as Additional Agents for Conditioning Before TCR Alpha/Beta Depleted HSCT in WAS Patients
|
Phase 2 | |
Terminated |
NCT00909363 -
Thrombocytopenia and Bleeding in Wiskott-Aldrich Syndrome (WAS) Patients
|
Phase 2 | |
Enrolling by invitation |
NCT01852370 -
Sequential Cadaveric Lung and Bone Marrow Transplant for Immune Deficiency Diseases
|
Phase 1/Phase 2 | |
Completed |
NCT03513328 -
Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT01410825 -
Pilot and Feasibility Study of Hematopoietic Stem Cell Gene Transfer for the Wiskott-Aldrich Syndrome
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT00004341 -
Study of Genetic and Molecular Defects in Primary Immunodeficiency Disorders
|
N/A | |
Completed |
NCT03399461 -
Targeted Literature Review and Subject Interviews in Wiskott-Aldrich Syndrome (WAS)
|
||
Active, not recruiting |
NCT03837483 -
A Clinical Study to Evaluate the Use of a Cryopreserved Formulation of OTL-103 in Subjects With Wiskott-Aldrich Syndrome
|
Phase 3 |